May 7 (Reuters) - AstraZeneca Plc may skip asking
the U.S. Food and Drug Administration for emergency-use
authorization for its COVID-19 vaccine, and instead pursue the
more time-intensive application for a full-fledged license to
sell the shot, the Wall Street Journal reported on Friday.
Such a step would further delay any rollout of the British
drugmaker's shots in the United States, according to the report
https://on.wsj.com/3eWvrry, which cited people familiar with the
matter.
(Reporting by Kanishka Singh in Bengaluru
Editing by Chris Reese)
Astrazeneca (AZN)